[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regentis Biomaterials Ltd (RGNT)

Regentis Biomaterials Ltd (RGNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

This Monthly Dividend Powerhouse Is Trading at a Bargain-Bin Valuation

The news of a deal between the U.S. and Iran to reopen the Strait of Hormuz sent markets higher yesterday. The S&P 500 and Nasdaq Composite gained 1.65% and 3.07%, respectively.

While the mood was positive on Wall Street, there were bearish price surprises alongside the bullish ones. 

Fundamentals

See More
  • Market Capitalization, $K 48,686
  • Shares Outstanding, K 5,179
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,650 K
  • EBIT $ 0 M
  • EBITDA $ -7 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.23 +395.29%
on 06/08/26
15.50 -60.65%
on 06/15/26
+3.95 (+183.92%)
since 05/15/26
3-Month
1.23 +395.29%
on 06/08/26
15.50 -60.65%
on 06/15/26
+2.92 (+91.82%)
since 03/16/26

Most Recent Stories

More News
This Monthly Dividend Powerhouse Is Trading at a Bargain-Bin Valuation

EPR Properties offers income investors a rare combination: a 6.3% monthly dividend yield, a conservative 73% payout ratio, and diversified exposure to experiential real estate well beyond movie theatres,...

CNK : 33.02 (+2.64%)
EPR : 59.10 (+1.27%)
AMC : 2.49 (+9.21%)
ELTX : 2.73 (-32.97%)
RGNT : 6.10 (-35.11%)
FUN : 24.45 (+4.76%)
Regentis Biomaterials (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC

Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R),...

RGNT : 6.10 (-35.11%)
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate

GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union

RGNT : 6.10 (-35.11%)
Regentis Biomaterials (NYSE American: RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure...

RGNT : 6.10 (-35.11%)
Regentis Biomaterials (NYSE American: RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant

Regentis Biomaterials Ltd. (NYSE Ame r ican: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positioning...

RGNT : 6.10 (-35.11%)
Regentis Biomaterials (NYSE American: RGNT) Is ‘One to Watch’

Regentis Biomaterials (NYSE American: RGNT) is taking aim at a $3 billion U.S. market with what could be the first true off-the-shelf solution for knee cartilage repair—no cells, no delays, no complexity....

RGNT : 6.10 (-35.11%)
Regentis Biomaterials (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair

Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both...

RGNT : 6.10 (-35.11%)
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon

Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption

RGNT : 6.10 (-35.11%)
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%

Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year

RGNT : 6.10 (-35.11%)
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update

$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinC

RGNT : 6.10 (-35.11%)

Business Summary

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.

See More

Key Turning Points

3rd Resistance Point 29.85
2nd Resistance Point 22.68
1st Resistance Point 16.04
Last Price 6.10
1st Support Level 2.22
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 15.50
Fibonacci 61.8% 10.05
Fibonacci 50% 8.37
Fibonacci 38.2% 6.68
Last Price 6.10
52-Week Low 1.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.